Assignee
ROUSSY INST GUSTAVE
FR·48 granted patents·31 pending applications·488 citations·filing 1995–2025
Top patents by PatentIndex Score
79 records- 0193US6939862B2Method for transferring nucleic acid into striated musclesROUSSY INST GUSTAVE·Filed 2001·Granted Sep 6, 2005·114 cites·30 claims
- 0289US10765710B2Combination of oncolytic virus with immune checkpoint modulatorsROUSSY INST GUSTAVE·Filed 2015·Granted Sep 8, 2020·13 cites·14 claims
- 0389US8865653B2Method of treatment for immunogenic treatment resistant cancerROUSSY INST GUSTAVE·Filed 2013·Granted Oct 21, 2014·7 cites·7 claims
- 0489US6723712B2Antiviral agent for use in treatment of cancerROUSSY INST GUSTAVE·Filed 2002·Granted Apr 20, 2004·52 cites·7 claims
- 0589US6410509B1Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatmentROUSSY INST GUSTAVE·Filed 2000·Granted Jun 25, 2002·23 cites·22 claims
- 0689US6143273ATherapeutic composition containing antibodies to soluble polypeptide fractions of LAG-3 proteinROUSSY INST GUSTAVE·Filed 1998·Granted Nov 7, 2000·80 cites·5 claims
- 0788US7378249B2Treatment of cancer using TLR3 agonistsROUSSY INST GUSTAVE·Filed 2005·Granted May 27, 2008·11 cites·12 claims
- 0886US7419669B2Peptide epitopes common to antigens of the same multigene familyROUSSY INST GUSTAVE·Filed 2003·Granted Sep 2, 2008·26 cites·3 claims
- 0982US5955300ASoluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodiesROUSSY INST GUSTAVE·Filed 1995·Granted Sep 21, 1999·35 cites·10 claims
- 1081US11684640B2Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 ab-basedROUSSY INST GUSTAVE·Filed 2017·Granted Jun 27, 2023·3 cites·4 claims
- 1181USRE38313ESoluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodiesROUSSY INST GUSTAVE·Filed 1995·Granted Nov 11, 2003·49 cites·15 claims
- 1280US10646521B2Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatmentROUSSY INST GUSTAVE·Filed 2014·Granted May 12, 2020·3 cites·20 claims
- 1380US2024393340A1Prognosis and predictive biomarkers and biological applications thereofROUSSY INST GUSTAVE·Filed 2024·Application pending·0 cites
- 1478US2022042016A1Identification of a JAK2 Mutation in Polycythemia VeraROUSSY INST GUSTAVE·Filed 2021·Application pending·0 cites
- 1573US11162100B2Identification of a JAK2 mutation in polycythemia veraROUSSY INST GUSTAVE·Filed 2020·Granted Nov 2, 2021·0 cites·8 claims
- 1672US12144839B2Microbiota composition, as a marker of responsiveness to anti-PD1/PD-L1/PD-L2 antibodies and use of microbial modulators for improving the efficacy of an anti-PD1/PD-L1/PD-L2 AB-based treatmentROUSSY INST GUSTAVE·Filed 2023·Granted Nov 19, 2024·0 cites·4 claims
- 1771US6875844B1Peptide compounds derived from a shifted ORF of the iCE geneROUSSY INST GUSTAVE·Filed 2000·Granted Apr 5, 2005·9 cites·7 claims
- 1870US10563200B2Identification of a JAK2 mutation in Polycythemia VeraROUSSY INST GUSTAVE·Filed 2019·Granted Feb 18, 2020·0 cites·3 claims
- 1969US6514708B2Process for detecting the malignant transformation of human cellsROUSSY INST GUSTAVE·Filed 2001·Granted Feb 4, 2003·2 cites·6 claims
- 2067US6855802B1Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapyROUSSY INST GUSTAVE·Filed 1999·Granted Feb 15, 2005·26 cites·8 claims
- 2167US6849452B1Methods for activating natural killer (NK) cells and means for carrying out said methodsROUSSY INST GUSTAVE·Filed 1999·Granted Feb 1, 2005·31 cites·15 claims
- 2267US2008253998A1Treatment of cancer using tlr3 agonistsROUSSY INST GUSTAVE·Filed 2008·Application pending·0 cites
- 2366US2026061029A1P21 Expressing Monocytes for Cancer Cell TherapyROUSSY INST GUSTAVE·Filed 2025·Application pending·0 cites
- 2462US10364430B2Identification of a JAK2 mutation in polycythemia veraROUSSY INST GUSTAVE·Filed 2014·Granted Jul 30, 2019·0 cites·3 claims
- 2562US7476496B2Method for preparing an extracellular matrix and its use for tumor cell cultureROUSSY INST GUSTAVE·Filed 2003·Granted Jan 13, 2009·1 cites·2 claims
- 2662US2016116480A1Prognosis and predictive biomarkers and biological applications thereofROUSSY INST GUSTAVE·Filed 2014·Application pending·0 cites
- 2761US2024301499A1Method for identifying hard-to-treat osteosarcoma patients at diagnosis and improving their outcome by providing new therapyROUSSY INST GUSTAVE·Filed 2022·Application pending·0 cites
- 2860US11471463B2Enhancers of cellular cannibalism for use to sensitize tumors to radiation therapyROUSSY INST GUSTAVE·Filed 2018·Granted Oct 18, 2022·0 cites·15 claims
- 2960US10969380B2Simultaneous detection of cannibalism and senescence as prognostic marker for cancerROUSSY INST GUSTAVE·Filed 2017·Granted Apr 6, 2021·0 cites·15 claims
- 3060US10125157B2Derivatives of oxazaphosphorines that are pre-activated, use and method of preparationROUSSY INST GUSTAVE·Filed 2016·Granted Nov 13, 2018·0 cites·7 claims
- 3159US11344586B2Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatmentROUSSY INST GUSTAVE·Filed 2020·Granted May 31, 2022·0 cites·5 claims
- 3257US12514902B2P21 expressing monocytes for cancer cell therapyROUSSY INST GUSTAVE·Filed 2020·Granted Jan 6, 2026·0 cites·16 claims
- 3357US9428530B2Derivatives of oxazaphosphorines that are pre-activated, use and method of preparationROUSSY INST GUSTAVE·Filed 2015·Granted Aug 30, 2016·0 cites·20 claims
- 3456US11517575B2Use of minaprine to reduce tumor growthROUSSY INST GUSTAVE·Filed 2019·Granted Dec 6, 2022·0 cites·7 claims
- 3556US2011229411A1Use of p2x7 pathway for assessing the sensitivity of a subject to a cancer treatmentROUSSY INST GUSTAVE·Filed 2008·Application pending·0 cites
- 3655US2025264457A1A biomarker and compositions to increase the therapeutic index of neoadjuvant immunotherapy in muscle-invasive urothelial carcinomaROUSSY INST GUSTAVE·Filed 2023·Application pending·0 cites
- 3755US2024398876A1Biological marker of intestinal dysbiosis, useful for predicting the response of a cancer patient to an anti-pdi drugROUSSY INST GUSTAVE·Filed 2022·Application pending·0 cites
- 3855US2004192637A1Antiviral agent for use in treatment of cancerROUSSY INST GUSTAVE·Filed 2003·Application pending·0 cites
- 3954US2008317811A1Treatment of Cancer Using Tlr3 AgonistsROUSSY INST GUSTAVE·Filed 2005·Application pending·0 cites
- 4054US2024288449A1Methods for diagnosing a cancer- or antibiotics-induced dysbiosis and their use for improving cancer treatment by immunotherapyROUSSY INST GUSTAVE·Filed 2022·Application pending·0 cites
- 4153US2020376052A1Combination of oncolytic virus with immune checkpoint modulatorsROUSSY INST GUSTAVE·Filed 2020·Application pending·0 cites
- 4250US12102672B2Immunogenic sequences from a phage tail length tape measure protein, bacteria expressing the same and their use in treating a cancerROUSSY INST GUSTAVE·Filed 2018·Granted Oct 1, 2024·0 cites·18 claims
- 4349US2020102353A1Human endogenous retroviral proteinROUSSY INST GUSTAVE·Filed 2019·Application pending·0 cites
- 4448US2025012805A1Products and uses thereof for predicting the sensitivity of a subject to cancer immunotherapy and for selecting optimized therapyROUSSY INST GUSTAVE·Filed 2022·Application pending·0 cites
- 4548US2006257380A1Use of sirnas for gene silencing in antigen presenting cellsROUSSY INST GUSTAVE·Filed 2002·Application pending·0 cites
- 4648US2024010990A1Methods for the Determination of Invasive Ability of Brain Tumour Cells and for the Diagnosis and Prognosis of Brain TumourROUSSY INST GUSTAVE·Filed 2021·Application pending·0 cites
- 4747US9557333B2Methods of treating gastrointestinal sarcoma patients depending on their sB7H6 serum levelROUSSY INST GUSTAVE·Filed 2013·Granted Jan 31, 2017·0 cites·5 claims
- 4847US2023302031A1Modulators Of Purinergic Receptors and Related Immune Checkpoint For Treating Acute Respiratory Distress SyndromeROUSSY INST GUSTAVE·Filed 2021·Application pending·0 cites
- 4947US2015232932A1Ankrd26 as a marker for diagnosis of thrombocytopeniasROUSSY INST GUSTAVE·Filed 2013·Application pending·0 cites
- 5047US2025161248A1Treating Chronic Myelomonocytic Leukemia with CXCL8 Receptor InhibitorsROUSSY INST GUSTAVE·Filed 2023·Application pending·0 cites
Showing the top 50 of 79 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →